Byondis
Evelyn Van Den Tweel is an experienced professional in clinical development, currently serving as Director of Clinical Development and Project Leader at Byondis since October 2014. Prior experience includes a role as Project Leader in Clinical R&D at Synthon from November 2004 to October 2014 and a tenure as a PhD student at UMC Utrecht, where research culminated in the thesis "Perinatal hypoxia-ischemia in the rat molecular pathways and neuroprotection." Educational background includes an MSc in Medical Biology from Utrecht University, completed in 2000, and earlier studies at Stellingwerf College from 1989 to 1995.
Byondis
1 followers
With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves: • Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications • Site-specific conjugation technology • Monoclonal antibodies (mAbs) • Highly selective, disease-targeting small molecules The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.